

NOV 10, 2025

Application to confirm share capital reduction

To Any Interested Party,

Medtronic Public Limited Company (the **Company**) filed application papers on Wednesday, 29 October 2025 with the Central Office of the High Court of Ireland for the purpose of its application to the Irish High Court seeking an order confirming the special resolution passed by over 75% of the Company's shareholders votes cast at the Company's Annual General Meeting on 16 October 2025, approving the reduction of the company capital of the Company pursuant to Sections 84 and 85 of the Irish Companies Act, 2014 (by the reduction of US\$37,201,999,999.80 standing to the credit of the Company's share premium account or such other amount as the High Court may determine) so that the reserve resulting from such reduction be treated as profits available for distribution as defined by Section 117 of the Irish Companies Act 2014 (the **Proposed Capital Reduction**).

At a directions hearing before the Commercial Division of the Irish High Court on Monday, 3 November 2025, the High Court directed that the Company's application to seek an order confirming the Proposed Capital Reduction be heard in the Commercial List of the High Court, sitting at the Four Courts, Inns Quay, Dublin 7, Ireland at **11:00 a.m. (GMT) on Wednesday, 26 November 2025** (the **Hearing**).

Further information in relation to the Hearing will be available on request from the solicitors for the Company, A&L Goodbody LLP, at the postal address or email address below.

Any interested party who wishes to attend and be heard at the hearing of the application is required to notify the Company's Solicitors, A&L Goodbody LLP (from whom copies of the Originating Notice of Motion and grounding Affidavit may be obtained at the postal address or email address given below) of their intention to do so by no later than **5p.m. GMT on Friday, 21 November 2025**, and file and serve on A&L Goodbody LLP, any Affidavit upon which they propose to rely upon by **5 p.m. GMT on Friday, 21 November 2025**.

A&L Goodbody LLP

Solicitors for the Company

25 North Wall Quay

Dublin 1

D01 H104

Ireland

bsmcgrath@algoodbody.com

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on [LinkedIn](#).

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Jane Di Leo

Public Relations

jane.e.dileo@medtronic.com

Ryan Weispfenning

Investor Relations

+1-763-505-4626

<https://news.medtronic.com/2025-11-10-Application-to-confirm-share-capital-reduction>